pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,123
stories
5d
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
6d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
6d
VertigoDx on firm ground with FDA greenlight for vertigo diagnostic system
fiercebiotech
6d
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
fiercebiotech
6d
Single pivotal trials: Stakeholders seek definitions, clarification about evidentiary standard
raps
6d
FDA call for new adcomm members signals renewed interest in outside advisors
raps
6d
Beam sues 2 biotechs, alleging theft of base editing trade secrets
biopharma dive
6d
STAT+: Overton won’t get a vote before midterms
stat
6d
UniQure tumbles with latest data for Huntington’s gene therapy
biopharma dive
6d
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years
biospace
6d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
6d
Summit snags $2B investment from AstraZeneca, clearing financial overhang
biospace
7d
STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
stat
7d
uniQure stock crashes as Huntington’s gene therapy data weaken
fiercebiotech
7d
STAT+: Drug pricing, Medicaid, and research funding: The key policy issues at stake in the midterms
stat
7d
3 steps for taking on Novartis in radiopharma: Curium up first
biospace
7d
Egetis Therapeutics' Emcitate cleared by FDA for rare X-linked genetic disease
endpoints
7d
Convergence: Regulators highlight efforts to streamline the European regulatory framework
raps
7d
Recon: FDA approves Egetis’ Emcitate for rare genetic disease; Novo buys rights to Chinese weight-loss pill in $2.6B deal
raps
7d
FDA Approves First Treatment for MCT8 Deficiency
fda press
7d
‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
fiercebiotech
7d
Kodiak skyrockets on positive study data for 2 eye drugs
biopharma dive
7d
Nonprofits' gene therapy for rare immune disease will cost $3.25M
endpoints
7d
Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor
endpoints
7d
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
biospace
7d
STAT+: It really is bleak out there, and list prices matter
stat
7d
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
biospace
7d
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
biospace
7d
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
7d
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
stat
← prev
page 2 of 38
next →
